Intermediate-risk childhood acute lymphoblastic leukemias: amsacrine + cytosine arabinoside versus intermediate-dose methotrexate for consolidation, and 6-mercaptopurine + methotrexate + vincristine versus monthly pulses for maintenance.

Schaison, G.; Leverger, G.; Bancillon, A; Marty, M; Olive, D.; Cornu, Guy; Griscelli, C; Lemerle, S; Harousseau, J L; Bonnet, M

Intermediate-risk childhood acute lymphoblastic leukemias: amsacrine + cytosine arabinoside versus intermediate-dose methotrexate for consolidation, and 6-mercaptopurine + methotrexate + vincristine versus monthly pulses for maintenance.

Schaison, G.

;

Leverger, G.

;

Bancillon, A

;

Marty, M

;

Bonnet, M

;et.al.

(1987) Haematology and Blood Transfusion — Vol. 30, p. 461-465 (1987)

Files

No attached file found for this publication.

Details

Authors

Schaison, G.
Author
Leverger, G.
Author
Bancillon, A
Author
Marty, M
Author
Cornu, GuyUCLouvain
Author
Bonnet, M
Author

Affiliations

UCLouvain

Citations

APA
Chicago
FWB

Schaison, G., Leverger, G., Bancillon, A., Marty, M., Olive, D., Cornu, G., Griscelli, C., Lemerle, S., Harousseau, J. L., & Bonnet, M. (1987). Intermediate-risk childhood acute lymphoblastic leukemias: amsacrine + cytosine arabinoside versus intermediate-dose methotrexate for consolidation, and 6-mercaptopurine + methotrexate + vincristine versus monthly pulses for maintenance. Haematology and Blood Transfusion, 30, 461-465. https://hdl.handle.net/2078.5/29327 (Original work published 1987)